View : 126 Download: 14
Risk of lymphadenopathy from SARS-CoV-2 vaccination in Korea: a self-controlled case series analysis
- Title
- Risk of lymphadenopathy from SARS-CoV-2 vaccination in Korea: a self-controlled case series analysis
- Authors
- Kim, Mi-Sook; Kim, Bongyoung; Choi, Jeong Pil; Choi, Nam-Kyong; Heo, Jung Yeon; Choi, Jun Yong; Lee, Joongyub; Kim, Sang Il
- Ewha Authors
- 최남경
- SCOPUS Author ID
- 최남경
- Issue Date
- 2023
- Journal Title
- EPIDEMIOLOGY AND HEALTH
- ISSN
- 2092-7193
- Citation
- EPIDEMIOLOGY AND HEALTH vol. 45
- Keywords
- COVID-19 vaccines; Lymphadenopathy; Self-controlled case series; Vaccine safety
- Publisher
- KOREAN SOC EPIDEMIOLOGY
- Indexed
- SCIE; SCOPUS
- Document Type
- Article
- Abstract
- OBJECTIVES: To assess the risk of lymphadenopathy following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination.METHODS: A self-controlled case series design was used to determine whether the risk of lymphadenopathy was higher in the 1-day to 42-day risk interval after coronavirus disease 2019 (COVID-19) vaccination compared to the control period. In addition, subgroup analyses were conducted according to baseline characteristics, time since vaccination, and sensitivity analyses adjusted for the length of the risk interval.RESULTS: The risk of developing lymphadenopathy in the risk interval (1-42 days) after COVID-19 vaccination compared to the control period was significantly increased, with a relative incidence (RI) of 1.17 (95% confidence interval [CI], 1.17 to 1.18) when the first, second, and third doses were combined. The RI was greater on the day of vaccination (1.47; 95% CI, 1.44 to 1.50). In subgroup analyses by baseline characteristics, a significantly increased risk or trend toward increased risk was observed in most subgroups except for those aged 70 years and older, with a significant increase in risk in younger individuals, those with a Charlson's comorbidity index < 5, and those who received mRNA vaccines (mRNA-1273 > BNT162b2). Within the 1-day to 42-day post-dose risk period, the relative risk was highest during the 1-day to 7-day post-dose period (1.59; 95% CI, 1.57 to 1.60) compared to the control period, and then the risk declined. In the sensitivity analysis, we found that the longer the risk window, the smaller the RI.CONCLUSIONS: SARS-CoV-2 vaccination is associated with a statistically significant increase in the risk of lymphadenopathy, and this risk was observed only with mRNA vaccines.
- DOI
- 10.4178/epih.e2023090|http://dx.doi.org/10.4178/epih.e2023090
- Appears in Collections:
- 신산업융합대학 > 융합보건학과 > Journal papers
- Files in This Item:
-
epih-45-e2023090.pdf(351.79 kB)
Download
- Export
- RIS (EndNote)
- XLS (Excel)
- XML